- Home
- SGLY vs INDP Comparison
SGLY vs INDP Comparison
Compare SGLY & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGLY
- INDP
- Stock Information
- Founded
- SGLY 2001
- INDP 2000
- Country
- SGLY United States
- INDP United States
- Employees
- SGLY N/A
- INDP N/A
- Industry
- SGLY
- INDP Biotechnology: Pharmaceutical Preparations
- Sector
- SGLY
- INDP Health Care
- Exchange
- SGLY Nasdaq
- INDP Nasdaq
- Market Cap
- SGLY 4.5M
- INDP 6.0M
- IPO Year
- SGLY 2008
- INDP N/A
- Fundamental
- Price
- SGLY $1.12
- INDP $2.28
- Analyst Decision
- SGLY
- INDP Strong Buy
- Analyst Count
- SGLY 0
- INDP 2
- Target Price
- SGLY N/A
- INDP $238.00
- AVG Volume (30 Days)
- SGLY 50.8K
- INDP 193.3K
- Earning Date
- SGLY 11-13-2025
- INDP 11-11-2025
- Dividend Yield
- SGLY N/A
- INDP N/A
- EPS Growth
- SGLY N/A
- INDP N/A
- EPS
- SGLY N/A
- INDP N/A
- Revenue
- SGLY $2,172,036.00
- INDP N/A
- Revenue This Year
- SGLY N/A
- INDP N/A
- Revenue Next Year
- SGLY N/A
- INDP N/A
- P/E Ratio
- SGLY N/A
- INDP N/A
- Revenue Growth
- SGLY N/A
- INDP N/A
- 52 Week Low
- SGLY $0.54
- INDP $2.26
- 52 Week High
- SGLY $5.49
- INDP $58.24
- Technical
- Relative Strength Index (RSI)
- SGLY 56.15
- INDP 20.16
- Support Level
- SGLY $0.94
- INDP $2.34
- Resistance Level
- SGLY $1.21
- INDP $2.86
- Average True Range (ATR)
- SGLY 0.08
- INDP 0.69
- MACD
- SGLY 0.00
- INDP -0.24
- Stochastic Oscillator
- SGLY 64.29
- INDP 1.22
About SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.